Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Massachusetts Eye and Ear Infirmary
The study is aimed to determine if oral administration of Mucinex® is effective in reducing the amount of corneal filaments and improving symptomology in subjects with filamentary keratitis. Subjects will be instructed to take 600 mg tablets of extended release Mucinex® twice a day (total dose is 1.2 g/day) for 4 weeks.
Age
18–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients with filamentary keratitis
18 years and older
You may not be if
Active ocular surface infection of any type
Recent ocular surgery (\<30 days) history of nephrolithiasis as Mucinex® has been associated in rare cases of development of kidney stones
Schirmer's test\<3mm
History of hypersensitivity to Mucinex®
Concurrent eye disease requiring immediate initiation of a new treatment (e.g. topical steroids) restriction for water intake can exacerbate the risk of nephrolithiasis.
